News coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 THERAPEUTICS earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.7366083273104 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

GTHX has been the subject of a number of analyst reports. Needham & Company LLC initiated coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued a “buy” rating and a $34.00 price target for the company. Cowen and Company reaffirmed a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, August 9th. Wedbush initiated coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company. Finally, J P Morgan Chase & Co initiated coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “overweight” rating and a $23.00 price target for the company.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at 25.87 on Friday. The company has a 50 day moving average price of $23.09 and a 200-day moving average price of $18.53. The stock’s market cap is $731.73 million. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.

G1 THERAPEUTICS (NASDAQ:GTHX) last issued its earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.48). On average, equities research analysts predict that G1 THERAPEUTICS will post ($2.92) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/07/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-g1-therapeutics-gthx-stock-price.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.